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The group of Congenital Disorders of Glycosylation (CDG)
is expanding rapidly since the first clinical description of
the N-glycosylation defect PMM2-CDG (CDG-Ia) in 1980
(Jaeken et al. 1980). Since then, more than 50 defects have
been identified in protein N-glycosylation (some of them
also associated with an O-glycosylation defect), in protein
O-glycosylation only and in lipid glycosylation (GPI
anchor and glycosphingolipid synthesis). Here, we provide
a simple approach to the clinical, biochemical and genetic
diagnosis of CDG due to a N-glycosylation defect
(including combined N- and O-glycosylation defects).
When to consider a CDG due to a N-glycosylation defect
Most CDG with a N-glycosylation defect are multi-organ
diseases with neurological involvement. Only few of
these CDG are known as non-neurological disorders,
such as MPI-CDG (de Lonlay and Seta 2009), DPM3-
CDG (Lefeber et al. 2009)a n dS E C 2 3 B - C D G( S c h w a r ze t
al. 2009). Nearly all organs have been reported to be
affected in CDG (Jaeken 2010). One should thus screen
for CDG (i) in any unexplained neurological syndrome,
particularly when associated with other organ disease, (ii)
and also in any unexplained syndrome even without
neurological involvement.
Experience gained in the last decade has shown that a
number of clinical clues might alert for a CDG and that
some of these clues might also provide a hint for a specific
CDG subtype, either in the CDG-I group (Morava et al.
2008) or in the CDG-II group (Mohamed et al. 2011).
These specific features include also the well known
abnormality in fat distribution or cutis laxa. A brief
overview of alerting clinical features is presented in Table 1
and currently known CDG subtypes are tabulated in Table 2.
A laboratory finding to be added to this list is syndromic
factor XI deficiency in CDG-I, and in an unknown number
of CDG-II defects.
How to screen for CDG due to a N-glycosylation defect
Since its introduction in 1984, isoelectric focusing (IEF) of
serum transferrin is still the method of choice for the
diagnosis of N-glycosylation disorders associated with
sialic acid deficiency (Jaeken et al. 1984). More recently,
HPLC (Helander et al. 2001) and capillary zone electro-
phoresis (Carchon et al. 2004) have been introduced as well
as mass spectrometry (Babovic-Vuksanovic and O'Brien
2007). In the absence of a protein polymorphism, the
isoelectric point of transferrin is determined only by its
glycosylation status. A protein polymorphism can be
identified by incubation of the sample with commercial
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thyroxine-binding globulin (TBG) or by analysis of
parental serum samples. In human plasma, the tetrasialo-
transferrin fraction is the most abundant form. Children
younger than 1 month can show mildly elevated under-
glycosylated transferrin isoforms as compared to older
children. Also, the diagnosis of CDG might be missed in
very young children, in whom the profile becomes
abnormal after 1–2 months of age. A few CDG patients
have been described with a normal profile particularly in
adolescent and adult age (V ermeer et al. 2007). Before
proceeding with further diagnostics, it is important to rule
out secondary causes of abnormal transferrin profiles, such
as fructosemia, galactosemia, alcohol abuse and bacterial
sialidase.
In general, two diagnostic types of abnormal profiles can
be distinguished (Fig. 1a): (i) a type 1 pattern in CDG-I,
characterized by an increase of di- and/or asialotransferrin;
(ii) a type 2 pattern in CDG-II, characterized by an increase
of tri-, di-, mono-and/or asialotransferrin.
The type 1 pattern (CDG-I) points to an assembly or
transfer defect of the dolichol-linked glycan (in the cytosol
or ER glycosylation pathway). Measurement of phospho-
mannomutase activity in fibroblasts or leukocytes is the
next step for further diagnostics because PMM2-CDG
(CDG-Ia) is by far the most frequent N-glycan assembly
defect. In case of a purely hepato-intestinal clinical presenta-
tion, the activity of phosphomannose isomerase should be
measured for diagnosis of MPI-CDG (CDG-Ib), which is a
treatable disease. A normal activity of these enzymes
necessitates analysis of the lipid-linked oligosaccharides
(LLO; more specifically dolichol-linked oligosaccharides) in
fibroblasts or other more specific assays to identifythe known
(or still unknown) CDG-I subtype. The recently identified
SRD5A3-CDG could be diagnosed directly by analysis of
plasma polyprenols (Morava et al. 2010).
Table 1 Overview of suggestive clinical features
Clinical features suggestive for a distinct CDG type Suspected gene defect Suggested analysis after transferrin screening
Syndromic fat pads and/or inverted nipples PMM2 PMM enzyme measurement
Chronic diarrhea MPI MPI enzyme measurement
ALG6 LLO analysis in fibroblasts
ALG8 “
Liver fibrosis MPI MPI enzyme measurement
Ichthyosis syndrome MPDU1 LLO analysis in fibroblasts
DOLK Mutation analysis
SRD5A3 Plasma polyprenols
Neurosyndromatic cataract and/or coloboma SRD5A3 Plasma polyprenols
ALG2 Mutation analysis
Neurosyndromatic sensorineural deafness ALG11 LLO analysis in fibroblasts
RFT1 Mutation analysis
Neurosyndromatic radio-ulnar synostosis MGA T2 Serum glycan profiling
Neurosyndromatic recurrent infections with unusually
high leukocytosis
SLC35C1 Bombay blood group
Serum glycan profiling
Neurological syndrome with Bombay bloodgroup SLC35C1 Serum glycan profiling
Mutation analysis
Cerebrocostomandibular syndrome COG1 Serum ApoC3 IEF
Mutation analysis
Neurological syndromes with episodic hyperthermia COG7 Serum ApoC3 IEF
Mutation analysis
Cutis laxa syndrome A TP6V0A2 Serum ApoC3 IEF
Mutation analysis
Congenital dyserythropoietic anemia type II or HEMPAS SEC23B Mutation analysis
Syndromic cardiomyopathy PMM2 PMM enzyme measurement
ALG1 LLO analysis in fibroblasts
DOLK Mutation analysis
DPM1
DPM3
850 J Inherit Metab Dis (2011) 34:849–852Fig. 1 Isofocusing techniques
in the screening for CDG. a.
Isofocusing of plasma transfer-
rin for detection of N-
glycosylation defects. Indicated
is the most abundant glycan
isoform of transferrin with two
bi-antennary N-glycans,
corresponding with tetrasialo-
transferrin. Lane 1: control,
lane 2: CDG-I profile, lane 3:
asialo type 2 profile, lane 4:
disialo type 2 profile. b.
Isofocusing of plasma apolipo-
protein C3 for detection of
mucin type O-glycosylation
defects. Lane 1: control, lane
2: ApoC3-0 profile, lane 3:
ApoC3-1 profile
CDG type# Gene, Protein TIEF ApoCIII Alternative assay
PMM2-CDG (Ia) PMM2, Phosphomannomutase Type I
MPI-CDG (Ib) MPI, Phosphomannose isomerase Type I
ALG6-CDG (Ic) ALG6, Glucosyltransferase I Type I
ALG3-CDG (Id) ALG3, Mannosyltransferase VI Type I
DPM1-CDG (Ie) DPM1, Dol-P-Man synthase Type I
MPDU1-CDG (If) MPDU1, Dol-P-Man utilization protein Type I
ALG12-CDG (Ig) ALG12, Mannosyltransferase VIII Type I
ALG8-CDG (Ih) ALG8, Glucosyltransferase II Type I
ALG2-CDG (Ii) ALG2, Mannosyltransferase II Type I
DPAGT1-CDG (Ij) DP AGT1, GlcNActransferase I Type I
ALG1-CDG (Ik) ALG1, Mannosyltransferase I Type I
ALG9-CDG (IL) ALG9, Mannosyltransferase VII Type I
DOLK-CDG (Im) DOLK, Dolichol kinase Type I
RFT1-CDG (In) RFT1, RFT1 protein Type I
DPM3-CDG (Io) DPM3, Dol-P-Man synthase Type I
ALG11-CDG (Ip) ALG11, Mannosyltransferase III Type I
SRD5A3-CDG (Iq) SRD5A3, Steroid5αreductase3 Type I
MGA T2-CDG (IIa) MGAT2, GlcNActransferase II Type II normal MS*
TUSC3-CDG TUSC3, Oligosaccharyltransferase subunit normal normal gene
MAGT1-CDG MAGT1, Oligosaccharyltransferase subunit
GCS1-CDG (IIb) MOGS, Glucosidase I (GCS1) normal normal Urine oligosaccharides
SLC35C1-CDG (IIc) SLC35C1, GDP-fucose transporter normal normal Bombay blood group, MS*
B4GALT1-CDG (IId) B4GALT1, Galactosyltransferase Type II normal MS*
SLC35A1-CDG (IIf) SLC35A1, CMP-NeuAc transporter normal normal CD15s on leukocytes
– COG1-8, COG 1–8 subunits Type II abnormal
– ATP6V0A2, vesicular H
(+)-A TPase
subunit a2
Type II abnormal
Table 2 Overview of current
CDG subtypes
#Official gene names were used
(www.genenames.org) to indi-
cate the new nomenclature. In
parenthesis (e.g. Ia for CDG-Ia)
the formerly used nomenclature.
*MS = serum N-glycan
profiling
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after glycan transfer in the ER or during Golgi glycosylation.
Not all processing defects can be picked up by transferrin IEF.
Patients with GCS1, SLC35C1 (fucose has no electric charge)
and SLC35A1 defects (formerly CDG-IIb, -IIc and CDG-IIf)
have been described with a normal transferrin IEF profile.
Type 2 patterns can show an asialo type 2 profile with
increased asialo- to trisialotransferrin, or a disialo type 2
profile with increased disialo- and trisialotransferrin. The next
step in the identification of the CDG-II subtypes is mass
spectrometry of isolated serum N-glycans (Guillard et al.
2011). This will permit to identify isolated N-glycosylation
defects as MGA T2-CDG (CDG-IIa) or B4GALT1-CDG
(CDG-IId) and secondary causes, but most CDG-II types are
associated with an aspecific glycan profile. In the latter
situation, the possibility of an associated mucin type O-
glycosylation defect should be investigated by isoelectrofocus-
ing of serum apolipoprotein C-III (APOC3). This protein
contains a single core 1 mucin type O-glycan on Thr-74.
Abnormal profiles (Fig. 1b) include an increased monosialo
APOC3 with decreased disialo APOC3 (a so-called APOC3-1
profile) or an increased asialo APOC3 (a so-called APOC3-0
profile) (Wopereis et al. 2005) .Y o u n gc h i l d r e ni nt h ef i r s t
months of life can present with an APOC3-2 profile in which
an increase of disialo APOC3 is observed. In our experience,
the latter pattern can also be observed in patients with severe
liver pathology.
Currently, no genetic glycosylation disorders have been
described with an isolated abnormality of the APOC3
profile. However, several defects are known with a
combined N- and O-glycosylation defect. In general, these
defects are characterized by abnormal functioning of the
secretory pathway, such as abnormal retrograde trafficking
or abnormal acidification. If the patient presents with
clinical symptoms of cutis laxa, mutation analysis of the
A TP6V0A2 gene is indicated. It should be noted that
A TP6V0A2-CDG patients younger than 6 months of age
can present with normal transferrin glycosylation, while
apolipoprotein C-III isofocusing is abnormal. In all other
cases, we recommend to look for a defect in one of the
COG (conserved oligomeric Golgi complex) subunits by
mutation analysis of the COG1-8 subunit genes.
The emerging innovative next-generation sequencing techni-
ques like whole-exome-sequencing will provide new opportu-
nities to unravel genetic causes for glycosylation disorders, such
as the CDG-II trafficking defects, but also the many glycosyl-
ation defects that cannot be identified via transferrin screening.
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